{"url":"https://lda.senate.gov/api/v1/filings/2e172cbe-1db2-4a72-b89c-ec0ce142f2c7/","filing_uuid":"2e172cbe-1db2-4a72-b89c-ec0ce142f2c7","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2025,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/2e172cbe-1db2-4a72-b89c-ec0ce142f2c7/print/","filing_document_content_type":"text/html","income":"80000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Tracy Spicer","dt_posted":"2025-04-21T15:19:39-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"401 9th St. NW","registrant_address_2":"Suite 720","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":72111,"url":"https://lda.senate.gov/api/v1/registrants/72111/","house_registrant_id":35940,"name":"AVENUE SOLUTIONS","description":"Government representation","address_1":"401 9th St. NW","address_2":"Suite 720","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"AMY TEJRAL","contact_telephone":"+1 202-347-9848","dt_updated":"2026-07-30T13:56:38.410932-04:00"},"client":{"id":165820,"url":"https://lda.senate.gov/api/v1/clients/165820/","client_id":1004443,"name":"OMEROS CORPORATION","general_description":"Biopharmaceutical company","client_government_entity":false,"client_self_select":null,"state":"WA","state_display":"Washington","country":"US","country_display":"United States of America","ppb_state":"WA","ppb_state_display":"Washington","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-02-28"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; S. 891, Bipartisan Health Care Act; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":23462,"prefix":null,"prefix_display":null,"first_name":"TRACY","nickname":null,"middle_name":null,"last_name":"SPICER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Issues related to the FDA and treatment for rare disease","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":23462,"prefix":null,"prefix_display":null,"first_name":"TRACY","nickname":null,"middle_name":null,"last_name":"SPICER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}